Salvagno, Camilla
Ciampricotti, Metamia
Tuit, Sander
Hau, Cheei-Sing
van Weverwijk, Antoinette
Coffelt, Seth B. http://orcid.org/0000-0003-2257-2862
Kersten, Kelly
Vrijland, Kim
Kos, Kevin
Ulas, Thomas
Song, Ji-Ying
Ooi, Chia-Huey
Rüttinger, Dominik
Cassier, Philippe A.
Jonkers, Jos
Schultze, Joachim L. http://orcid.org/0000-0003-2812-9853
Ries, Carola H. http://orcid.org/0000-0002-1855-8745
de Visser, Karin E. http://orcid.org/0000-0002-0293-868X
Article History
Received: 14 December 2018
Accepted: 13 February 2019
First Online: 18 March 2019
Competing interests
: C.H.R., C.-H.O. and D.R. are employees of F. Hoffman La Roche. C.H.R. is an inventor of granted and pending patent applications relating to emactuzumab and a stockholder in F. Hoffman La Roche. F. Hoffman La Roche provided financial research support for the experiments with anti-CSF-1R. P.A.C. received funding from Roche for the described clinical trial and other Roche-sponsored studies.